Arcus and AstraZeneca enter trial collaboration for renal cancer treatment

Arcus Biosciences has announced a clinical trial partnership with AstraZeneca to assess the combination of casdatifan (AB521) and volrustomig in patients with clear cell renal cell carcinoma (ccRCC).